StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — U.S. reported growth YoY (%) (%)

Form 8-K Key Product Revenues Schedule

QuarterlyAnnual
Latest, Q4 2024
-13.7%
Period ended Dec 31, 2024
Change on a year earlier
-27.2 pts
13.5% in Q4 2023
History
14 quarters
Since Q3 2021
Sources
14
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRestasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — U.S. reported growth YoY (%) (%)Year on yearSource
Q4 2024Dec 31, 2024-13.7%-27.2 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 2024-92.5%-71.8 ptsForm 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 2024-77.3%-31.5 ptsForm 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 2024-44.1%+22.4 ptsForm 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 202313.5%+84.0 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 2023-20.7%+36.0 ptsForm 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 2023-45.8%+5.7 ptsForm 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 2023-66.5%-54.6 ptsForm 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 2022-70.5%-75.4 ptsForm 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 2022-56.7%-64.2 ptsForm 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗
Q2 2022Jun 30, 2022-51.5%–Form 8-K (abbv-20220630xexhibit991.htm, filed 2022-07-29) ↗
Q1 2022Mar 31, 2022-11.9%–Form 8-K (abbv-20220331xexhibit991.htm, filed 2022-04-29) ↗
Q4 2021Dec 31, 20214.9%–Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗
Q3 2021Sep 30, 20217.5%–Form 8-K (abbv-20210930xexhibit991.htm, filed 2021-10-29) ↗

Cite this data

StockData. (2026). AbbVie Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — U.S. reported growth YoY (%) (%), quarterly Q3 2021–Q4 2024 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/restasis_us_rep_yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.